Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 312

Sort by

Sort Order Select

Journal Articles

MO-TRANS update: A randomized, double-blind, placebo-controlled, multi-center phase III study of mocravimod (MOC) as maintenance treatment in AML patients undergoing allogeneic hematopoietic cell transplantation

Marcos de Lima, Gabriela Sanchez-Petitto, Edmund Waller, Charles Craddock, Maria Calbacho, Giancarlo Fatobene, Daniel Ghali, Jennifer Rubel, Stephan Oehen, Jens Hasskarl

Blood (2025) 146 (Supplement 1): 6086.

https://doi.org/10.1182/blood-2025-6086

Published: 2025

Journal Articles

Tocilizumab for cytokine release syndrome after allogeneic hematopoietic stem cell transplantation with post-transplant cyclophosphamide

Tuan Phan, Evandro Bezerra, Hannah Choe, Nathan Denlinger, Marcos de Lima, Sam Penza, Gabriela Sanchez-Petitto, Jeremy Sen, Polina Shindiapina, Justin Tossey, Sumithira Vasu, Sarah Wall, Jiasheng Wang

Blood (2025) 146 (Supplement 1): 4217.

https://doi.org/10.1182/blood-2025-4217

Published: 2025

Journal Articles

Results of the first Latin American point of care manufactured, Phase I anti- CD19 CAR-T study (CARTHIAE) for Relapsed/Refractory B-cell neoplasms

Blood (2025) 146 (Supplement 1): 2405.

https://doi.org/10.1182/blood-2025-2405

Published: 2025

Journal Articles

First report of successful, lifesaving and timely graft rescue using an off-the-shelf cryopreserved, cadaveric marrow in myeloablative transplant with an unexpected unavailability of a living matched unrelated donor.

Sumithira Vasu, Nicole Szuminski, Sagar Munjal, Justin Tossey, Jeremy Sen, Preethi Prasad, Beth Daneault, Ashley Krull, Lynn Odonnell, Hillary Bradbury, Marcos de Lima, Gabriela Sanchez-Petitto

Blood (2025) 146 (Supplement 1): 7708.

https://doi.org/10.1182/blood-2025-7708

Published: 2025

Journal Articles

Phase 1 clinical trial of point-of-care manufactured, fully human anti-CD19 CAR-T cells for treatment of Relapsed/Refractory lymphoid malignancies

Nikki Agarwal, Brenda Cooper, Molly Gallogly, Leland Metheny, Changchun Deng, Ok-Kyong Chaekal, Rebecca Klisovic, Jane Reese, Dina Schneider, Rimas Orentas, Marcos de Lima, Koen van Besien, David Wald, Paolo Caimi, Ben Tomlinson

Blood (2025) 146 (Supplement 1): 5925.

https://doi.org/10.1182/blood-2025-5925

Published: 2025

Journal Articles

Baseline immune and proteomic profiling predicts response and resistance to CD19 CAR T-cell therapy in B-cell non-Hodgkin lymphoma: Insights from a decentralized manufacturing clinical trial

Arun Arunachalam, Jessica Kerr, Jane Reese, Armin Ghobadi, David Wald, Rimas Orentas, Boro Dropulic, Paolo Caimi, Marcos de Lima, J. Joseph Melenhorst

Blood (2025) 146 (Supplement 1): 567.

https://doi.org/10.1182/blood-2025-567

Published: 2025

Journal Articles

CD34 selected stem cell boost provides robust outcomes in patients with poor graft function

Sayan Mullick Chowdhury, Qiuhong Zhao, Sarah Wall, Hannah Choe, Sam Penza, Evandro Bezerra, Lynn Odonnell, Merle Kolk, Michael Daunov, Ashley Krull, Marcos de Lima, Leland Metheny, Sumithira Vasu

Blood (2025) 146 (Supplement 1): 7790.

https://doi.org/10.1182/blood-2025-7790

Published: 2025

Journal Articles

Ibrutinib in the treatment of allogeneic stem cell transplant-related pure red cell aplasia: A single center experience

Roberta Azbell, Lexus Frazier, Justin Tossey, Marcos de Lima, Sarah Wall

Blood (2025) 146 (Supplement 1): 2443.

https://doi.org/10.1182/blood-2025-2443

Published: 2025

Journal Articles

Locally deployed large language models for automated data curation in allogeneic hematopoietic stem cell transplantation

Jiasheng Wang, Tuan Phan, Pedro Silberman, Evandro Bezerra, Jonathan Brammer, Hannah Choe, Nathan Denlinger, Marcos de Lima, Sam Penza, Gabriela Sanchez-Petitto, Polina Shindiapina, Sumithira Vasu, Sarah Wall, Reza Averly, Xia Ning, Bradley Blaser

Blood (2025) 146 (Supplement 1): 4352.

https://doi.org/10.1182/blood-2025-4352

Published: 2025

Journal Articles

Real world experience of alpha-1 antitrypsin in steroid-refractory acute graft versus host disease: Higher durable response rate compared to ruxolitinib

Henry Castellani, Jean Caputo, Qiuhong Zhao, Justin Tossey, Marcos de Lima, Sumithira Vasu, Sarah Wall, Gabriela Sanchez-Petitto, Evandro Bezerra, Hannah Choe

Blood (2025) 146 (Supplement 1): 4233.

https://doi.org/10.1182/blood-2025-4233

Published: 2025

Journal Articles

Safety and immunomodulatory effects of siltuximab prophylaxis prior to standard of care CD19 directed chimeric antigen receptor T-cell (CD19.CART) therapy for B-cell lymphomas: Final phase I trial results

Blood (2025) 146 (Supplement 1): 2385.

https://doi.org/10.1182/blood-2025-2385

Published: 2025

Journal Articles

Total marrow irradiation-based, intensified reduced-intensity conditioning regimen for haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide: A prospective study

Leonardo Arcuri, Mariana Kerbauy, Lucila Kerbauy, Juliana Rocha, Carolina Marques, Tarcila Datoguia, Jade Zezzi Martins do Nascimento, Ana de Rezende, Eduardo Weltman, Roberto Sakuraba, Andreza Ribeiro, Marcos de Lima, Nelson Hamerschlak

Blood (2025) 146 (Supplement 1): 7738.

https://doi.org/10.1182/blood-2025-7738

Published: 2025

Journal Articles

Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease

Blood (2025) 146 (Supplement 1): 1935.

https://doi.org/10.1182/blood-2025-1935

Published: 2025

Journal Articles

Total marrow irradiation-based, intensified reduced-intensity conditioning regimen for hematopoietic cell transplantation in patients aged 60 years or older: A prospective study

Leonardo Arcuri, Mariana Kerbauy, Lucila Kerbauy, Juliana Rocha, Carolina Marques, Tarcila Datoguia, Jade Zezzi Martins do Nascimento, Ana de Rezende, Eduardo Weltman, Andreza Ribeiro, Marcos de Lima, Nelson Hamerschlak

Blood (2025) 146 (Supplement 1): 2439.

https://doi.org/10.1182/blood-2025-2439

Published: 2025

Journal Articles

Steroid Prophylaxis in Patients Receiving CAR T-Cell Therapy for Relapsed and Refractory Non-Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 4507.

https://doi.org/10.1182/blood-2024-206559

Published: 2024

Journal Articles

Spatial Tissue Analysis of Secondary Sarcoma Following CAR T Cell Therapy for B Cell Lymphoma

Dina Schneider, Jia-Jye Lee, Jinling Wang, Robert Pinard, Peirong Hu, Kun Luo, Ngoc Tran, Yazeed Sawalha, Nathan Denlinger, Evandro Bezerra, Pradyot Dash, Ashley Angell Krull, Lynn O'Donnell, Lapo Alinari, Dan Jones, Marcos de Lima, Sumithira Vasu

Blood (2024) 144 (Supplement 1): 7139.

https://doi.org/10.1182/blood-2024-203633

Published: 2024

Journal Articles

Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies

Blood (2024) 144 (Supplement 1): 2078.

https://doi.org/10.1182/blood-2024-207532

Published: 2024

Journal Articles

Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2950.

https://doi.org/10.1182/blood-2024-194922

Published: 2024

Journal Articles

Phase I Study Results of UF-Kure19, a CAR-T Product Manufactured in Less Than 1 Day, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma

Changchun Deng, Paolo F. Caimi, Umar Farooq, Nethrie Idippily, Maria Florencia Giraudo, Jane S. Reese, Sarah Kleinsorge-Block, Daniel Caley, Ryan Stadel, Koen van Besien, Marcos de Lima, Arun Kumar Arunachalam, J. Joseph Melenhorst, David Wald

Blood (2024) 144 (Supplement 1): 94.

https://doi.org/10.1182/blood-2024-206596

Published: 2024

Journal Articles

Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy Is Associated with Inferior Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3747.

https://doi.org/10.1182/blood-2024-203798

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

MO-TRANS update: A randomized, double-blind, placebo-controlled, multi-center phase III study of mocravimod (MOC) as maintenance treatment in AML patients undergoing allogeneic hematopoietic cell transplantation

Tocilizumab for cytokine release syndrome after allogeneic hematopoietic stem cell transplantation with post-transplant cyclophosphamide

Results of the first Latin American point of care manufactured, Phase I anti- CD19 CAR-T study (CARTHIAE) for Relapsed/Refractory B-cell neoplasms

First report of successful, lifesaving and timely graft rescue using an off-the-shelf cryopreserved, cadaveric marrow in myeloablative transplant with an unexpected unavailability of a living matched unrelated donor.

Phase 1 clinical trial of point-of-care manufactured, fully human anti-CD19 CAR-T cells for treatment of Relapsed/Refractory lymphoid malignancies

Baseline immune and proteomic profiling predicts response and resistance to CD19 CAR T-cell therapy in B-cell non-Hodgkin lymphoma: Insights from a decentralized manufacturing clinical trial

CD34 selected stem cell boost provides robust outcomes in patients with poor graft function

Ibrutinib in the treatment of allogeneic stem cell transplant-related pure red cell aplasia: A single center experience

Locally deployed large language models for automated data curation in allogeneic hematopoietic stem cell transplantation

Real world experience of alpha-1 antitrypsin in steroid-refractory acute graft versus host disease: Higher durable response rate compared to ruxolitinib

Safety and immunomodulatory effects of siltuximab prophylaxis prior to standard of care CD19 directed chimeric antigen receptor T-cell (CD19.CART) therapy for B-cell lymphomas: Final phase I trial results

Total marrow irradiation-based, intensified reduced-intensity conditioning regimen for haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide: A prospective study

Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease

Total marrow irradiation-based, intensified reduced-intensity conditioning regimen for hematopoietic cell transplantation in patients aged 60 years or older: A prospective study

Steroid Prophylaxis in Patients Receiving CAR T-Cell Therapy for Relapsed and Refractory Non-Hodgkin Lymphoma

Spatial Tissue Analysis of Secondary Sarcoma Following CAR T Cell Therapy for B Cell Lymphoma

Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies

Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia

Phase I Study Results of UF-Kure19, a CAR-T Product Manufactured in Less Than 1 Day, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma

Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy Is Associated with Inferior Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only